Literature DB >> 22120850

17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.

Paul Merlob1, Bracha Stahl, Gil Klinger.   

Abstract

Use of 17-alpha-hydroxyprogesterone caproate for the prevention of spontaneous preterm birth in women at risk is reviewed. Early studies regarding this topic reached contradicting conclusions, however recent studies showed that weekly injections of 17-alpha-hydroxyprogesterone caproate beginning at 16-20 weeks' gestation resulted in a substantial reduction in the rate of spontaneous recurrent preterm birth. Long-term follow-up of children exposed in-utero to the drug has shown normal growth and development and normal scores for gender specific roles. In conclusion, 17-alpha-hydroxyprogesterone caproate is currently the only drug with sufficient evidence to support its use for prevention of spontaneous recurrent preterm birth.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22120850     DOI： 10.1016/j.reprotox.2011.10.017

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN： 0890-6238            Impact factor:   3.143


  7 in total

1.  17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.

Authors:  Lorena M Amaral; Denise C Cornelius; Ashlyn Harmon; Janae Moseley; James N Martin; Babbette LaMarca
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Progesterone blunts vascular endothelial cell secretion of endothelin-1 in response to placental ischemia.

Authors:  Luissa V Kiprono; Kedra Wallace; Janae Moseley; James Martin; Babbette Lamarca
Journal:  Am J Obstet Gynecol       Date:  2013-03-29       Impact factor: 8.661

3.  The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.

Authors:  Martha L Bustos; Steve N Caritis; Kathleen A Jablonski; Uma M Reddy; Yoram Sorokin; Tracy Manuck; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; Alan M Peaceman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan M Ramin
Journal:  Am J Obstet Gynecol       Date:  2017-05-15       Impact factor: 8.661

4.  Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger
Journal:  Compr Physiol       Date:  2020-12-09       Impact factor: 9.090

5.  17-Hydroxyprogesterone caproate improves T cells and NK cells in response to placental ischemia; new mechanisms of action for an old drug.

Authors:  Jamil T Elfarra; Jesse N Cottrell; Denise C Cornelius; Mark W Cunningham; Jessica L Faulkner; Tarek Ibrahim; Babbette Lamarca; Lorena M Amaral
Journal:  Pregnancy Hypertens       Date:  2019-12-02       Impact factor: 2.899

6.  Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy.

Authors:  Lorena M Amaral; Luissa Kiprono; Denise C Cornelius; Carrie Shoemaker; Kedra Wallace; Janae Moseley; Gerd Wallukat; James N Martin; Ralf Dechend; Babbette LaMarca
Journal:  Am J Obstet Gynecol       Date:  2014-02-15       Impact factor: 8.661

7.  Progesterone-induced blocking factor improves blood pressure, inflammation, and pup weight in response to reduced uterine perfusion pressure (RUPP).

Authors:  Jesse N Cottrell; Alexis C Witcher; Kyleigh Comley; Mark W Cunningham; Tarek Ibrahim; Denise C Cornelius; Babbette LaMarca; Lorena M Amaral
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-02-03       Impact factor: 3.210
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.